Heterogeneous Catalysis Reaction Optimization
At the forefront of flow reactor design, FlowSyn™ from Uniqsis sets the standard for automated optimization of heterogeneous catalysis reactions.
Eppendorf Simplifies Bioprocess Data Acquisition
Eppendorf introduces the Bioprocess Autosampler, which facilitates sampling 24/7 in short and regular intervals, gaining complete datasets.
Waters Corporation Unveils MaxPeak Premier Oligonucleotide Columns
Waters Corp introduces its newest MaxPeak Premier Oligonucleotide Columns to support applications for nucleic acid therapeutics and cell and gene therapies.
Samsara Therapeutics Unveils Promising Autophagy Drug Candidate
Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.
Gyros Protein Technologies Introduces Gyrolab Generic Cyno ADA Kit Reagents
Gyros Protein Technologies AB has announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.
Holistic IoT Device and Lab Management Solution
Eppendorf has partnered with Clustermarket to offer a smooth integration between the Clustermarket equipment scheduler and Eppendorf’s VisioNize® Lab Suite.
Personalis, ABRCC and Criterium Announce Major Prospective Clinical Trial
Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.
Agilent Expands Family of Intelligent GC Systems
Agilent Technologies Inc. has announced the release of the Agilent 8697 Headspace Sampler -XL Tray with 120 vial capacity.
HORIBA Introduces Simple PCR Test for Faster Strangles Diagnosis
HORIBA is highlighting the benefits of fast PCR testing for Streptococcus equi in under two hours.
Pharmacogenomics Research Could Save NHS at Least £41 Million Annually
An analysis of NHS prescriptions data has revealed the huge potential for pharmacogenomics to reduce ineffective prescribing and adverse effects, which could save millions of pounds for the NHS.